Drugs Made In America Acquisition II Corp.
Drugs Made In America Acquisition II Corp. is a Cayman Islands blank check company formed to complete a merger, share exchange, asset acquisition, recapitalization, or similar business combination. It raised capital through an IPO and private placement and is currently searching for a target, with a stated focus on the pharmaceutical industry.
Fiscal year 2025 · change from previous year
Development 2025–2025
Business
Share of revenue{"• SPAC structure for a future business combination","• IPO units with ordinary shares and shareholder rights","• Private placement units sold to sponsor and underwriters","• Trust-account capital used to fund an acquisition","• Public-company acquisition and due diligence process"}
Capital raised to acquire an operating company through a future business combination.
Customers
The company does not sell products or services to end customers today; its counterparties are investors, the sponsor, underwriters, and ultimately a target business for a merger or acquisition. After a business combination, its customer base would depend entirely on the acquired operating company. For now, the economic purpose is to provide public-market acquisition capital and a listing path for a private business, especially in pharmaceuticals.
Buy IPO units and rights for exposure to a future acquisition and potential redemption value.
Provide private placement capital and support the transaction structure and search process.
Would exchange their business for public-company access, capital, and liquidity in a merger.
Potential operating businesses in the pharma sector that fit the company's stated search mandate.
Strategy
The company’s near-term strategy is to identify and complete an initial business combination, using IPO proceeds, private placement funds, and potentially debt or equity. Management has stated a preference for pharmaceutical targets, which narrows the search universe and may improve sector fit, but also makes execution dependent on deal sourcing and diligence.
The company has no operating business yet, so deal sourcing is the core value-creation task.
Completion of a transaction converts the SPAC from a cash shell into an operating company.
Investor redemptions can reduce cash available for the deal and affect closing certainty.
Geography
The company is incorporated in the Cayman Islands but is managed from the United States and listed in the U.S. public markets. Its current economic activity is concentrated in capital raising and target screening rather than operating geography, so exposure is mainly tied to where a future acquisition is sourced and operated. The stated search focus on pharmaceuticals could eventually shift the geographic profile materially after a business combination.
Risks
The company is pre-revenue and depends on successfully finding and closing a business combination, so execution risk is the dominant issue. As a SPAC, it also faces redemption risk, deal-diligence risk, and public-market volatility, while any future operating risks will depend on the acquired business.
The company exists to acquire a business; without a deal, it cannot transition into operations.
Exposure: All current capital and the SPAC structure
Investors may redeem shares before closing, reducing the cash available to fund the transaction.
Exposure: Trust account funding and deal financing
A weak or overvalued acquisition can destroy value after closing.
Exposure: Pharmaceutical target screening
Legal, accounting, and due diligence expenses continue while the company searches for a target.
Exposure: Pre-combination overhead
Accounting
Judgemental itemsInterest earned on cash and investments is one of the few sources of pre-combination income.
Impact: Offsets general and administrative expenses and reduces reported net loss
A portion of underwriting compensation is payable only if a business combination is completed.
Impact: Creates a contingent transaction cost tied to deal success
Legal, audit, and compliance costs are incurred before any operating business exists.
Impact: Drive pre-combination losses and reduce net assets
The IPO units include ordinary shares and rights that must be assessed for accounting treatment.
Impact: Affects balance sheet presentation and dilution analysis
Similar listed companies
Publicly listed companies with a comparable business focus.
Drugs Made In America Acquisition Corp.
DMAA · Blank Checks
Future Vision II Acquisition Corp.
FVNNR · Services-Computer Integrated Systems Design
FACT II Acquisition Corp
FACTW · Aircraft Parts & Auxiliary Equipment, NEC
Iron Horse Acquisition II Corp.
IRHOU · Services-Business Services, NEC
Horizon Space Acquisition II Corp.
Blank Checks
Columbus Acquisition Corp/Cayman Islands
COLAU · Blank Checks
Columbus Acquisition Corp/Cayman Islands is a Cayman Islands blank check company formed to complete a merger, share exchange, asset acquisition, recapitalization, or similar business combination.
Last updated: 28/04/2026